In this review we discuss the current literature on the effects of type I interferons (IFN) and their downstream effectors on vascular growth in experimental models in vitro and in vivo. In addition to its well-documented role in angiogenesis, that is, the growth of new capillaries from existing vessels, we will also describe emerging evidence and mechanisms by which type I IFN may inhibit arteriogenesis, that is, the expansive remodeling of existing collateral arteries. Crucial in both processes is the common role of circulating monocytes, which are known to act as pivotal cellular modulators in revascularization through secreted chemokines, proteases, and growth factors. These secreted molecules, which are all modulated by IFN signaling, act via degradation of the extracellular matrix and by stimulating the proliferation of vascular smooth muscle cells and endothelial cells. Thus, next to the antiviral and immunomodulatory activities of type I IFNs, a potent role of IFN-β as modulator of revascularization is now emerging and may be considered a potential clinical target for the stimulation of angiogenesis and arteriogenesis in ill-perfused tissues.
Get full access to this article
View all access options for this article.
References
1.
AplinAC, LigrestiG, FogelE, ZorziP, SmithK, NicosiaRF. 2014. Regulation of angiogenesis, mural cell recruitment and adventitial macrophage behavior by Toll-like receptors. Angiogenesis, 17(1):147–161.
2.
ArrasM, ItoWD, ScholzD, WinklerB, SchaperJ, SchaperW. 1998. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest, 101(1):40–50.
3.
ArslanF, de KleijnDP, PasterkampG. 2011. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol, 8(5):292–300.
4.
ArslanF, SmeetsMB, O'NeillLA, KeoghB, McGuirkP, TimmersL, TersteegC, HoeferIE, DoevendansPA, PasterkampG, de KleijnDP. 2010. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation, 121(1):80–90.
5.
BaechlerEC, BatliwallaFM, KarypisG, GaffneyPM, OrtmannWA, EspeKJ, SharkKB, GrandeWJ, HughesKM, KapurV, GregersenPK, BehrensTW. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A, 100(5):2610–2615.
6.
BaechlerEC, BauerJW, SlatteryCA, OrtmannWA, EspeKJ, NovitzkeJ, YtterbergSR, GregersenPK, BehrensTW, ReedAM. 2007. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med, 13(1–2):59–68.
7.
BastiaansenAJ, KarperJC, WezelA, de BoerHC, WeltenSM, de JongRC, PetersEA, de VriesMR, van Oeveren-RietdijkAM, van ZonneveldAJ, HammingJF, NossentAY, QuaxPH. 2014. TLR4 accessory molecule RP105 (CD180) regulates monocyte-driven arteriogenesis in a murine hind limb ischemia model. PLoS One, 9(6):e99882.
8.
BekiszJ, SchmeisserH, HernandezJ, GoldmanND, ZoonKC. 2004. Human interferons alpha, beta and omega. Growth Factors, 22(4):243–251.
9.
BillottetC, QuemenerC, BikfalviA. 2013. CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta, 1836(2):287–295.
10.
BogerRH, Bode-BogerSM, TsaoPS, LinPS, ChanJR, CookeJP. 2000. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol, 36(7):2287–2295.
11.
BordenEC, SenGC, UzeG, SilvermanRH, RansohoffRM, FosterGR, StarkGR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov, 6(12):975–990.
12.
BosCL, van BaarsenLG, TimmerTC, OverbeekMJ, BasoskiNM, RustenburgF, BaggenJM, ThiesenHJ, DijkmansBA, van der Pouw KraanTC, VoskuylAE, VerweijCL. 2009. Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes Immun, 10(3):210–218.
13.
CaiWJ, KoltaiS, KocsisE, ScholzD, KostinS, LuoX, SchaperW, SchaperJ. 2003. Remodeling of the adventitia during coronary arteriogenesis. Am J Physiol Heart Circ Physiol, 284(1):H31–H40.
14.
CaoG, SuJ, LuW, ZhangF, ZhaoG, MarteralliD, DongZ. 2001. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther, 8(7):497–505.
15.
ChenZ, RubinJ, TzimaE. 2010. Role of PECAM-1 in arteriogenesis and specification of preexisting collaterals. Circ Res, 107(11):1355–1363.
16.
CoelhoLF, Magno de FreitasAG, MennechetFJ, BlangyA, UzeG. 2005. Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci U S A, 102(33):11917–11922.
ErdmannJ, VitaleG, van KoetsveldPM, CrozeE, Sprij-MooijDM, HoflandLJ, van EijckCH. 2011. Effects of interferons alpha/beta on the proliferation of human micro- and macrovascular endothelial cells. J Interferon Cytokine Res, 31(5):451–458.
24.
FaberJE, ChilianWM, DeindlE, van RoyenN, SimonsM. 2014. A brief etymology of the collateral circulation. Arterioscler Thromb Vasc Biol, 34(9):1854–1859.
25.
FidlerIJ, YanoS, ZhangRD, FujimakiT, BucanaCD. 2002. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol, 3(1):53–57.
26.
GalisZS, JohnsonC, GodinD, MagidR, ShipleyJM, SeniorRM, IvanE. 2002. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res, 91(9):852–859.
27.
GershBJ, SliwaK, MayosiBM, YusufS. 2010. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J, 31(6):642–648.
28.
GlaserJ, GonzalezR, PerreauVM, CotmanCW, KeirsteadHS. 2004. Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury. J Neurosci Res, 77(5):701–708.
29.
GoossensP, GijbelsMJ, ZerneckeA, EijgelaarW, VergouweMN, van der MadeI, VanderlochtJ, BeckersL, BuurmanWA, DaemenMJ, KalinkeU, WeberC, LutgensE, de WintherMP. 2010. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab, 12(2):142–153.
HataT, TakahashiM, HidaS, KawaguchiM, KashimaY, UsuiF, MorimotoH, NishiyamaA, IzawaA, KoyamaJ, IwakuraY, TakiS, IkedaU. 2011. Critical role of Th17 cells in inflammation and neovascularization after ischaemia. Cardiovasc Res, 90(2):364–372.
32.
HeilM. SchaperW. 2007. Insights into pathways of arteriogenesis. Curr Pharm Biotechnol, 8(1):35–42.
33.
HoeferIE, GrundmannS, van RoyenN, VoskuilM, SchirmerSH, UlusansS, BodeC, BuschmannIR, PiekJJ. 2005. Leukocyte subpopulations and arteriogenesis: specific role of monocytes, lymphocytes and granulocytes. Atherosclerosis, 181(2):285–293.
HondaK, TakaokaA, TaniguchiT. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity, 25(3):349–360.
36.
HondaK, TaniguchiT. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol, 6(9):644–658.
37.
HuangS, BucanaCD, Van ArsdallM, FidlerIJ. 2002. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene, 21(16):2504–2512.
38.
HuangZ, YangY, JiangY, ShaoJ, SunX, ChenJ, DongL, ZhangJ. 2013. Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers. Biomaterials, 34(3):746–755.
39.
IndraccoloS. 2010. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity, 43(3):244–247.
40.
IvashkivLB, DonlinLT. 2014. Regulation of type I interferon responses. Nat Rev Immunol, 14(1):36–49.
41.
IzawaJI, SweeneyP, PerrotteP, KedarD, DongZ, SlatonJW, KarashimaT, InoueK, BenedictWF, DinneyCP. 2002. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res, 8(4):1258–1270.
42.
JablonskaJ, LeschnerS, WestphalK, LienenklausS, WeissS. 2010. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest, 120(4):1151–1164.
43.
JavedA, RederAT. 2006. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther, 110(1):35–56.
44.
KallioliasGD, IvashkivLB. 2010. Overview of the biology of type I interferons. Arthritis Res Ther, 12Suppl 1:S1–S9.
45.
KaoJ, KobashigawaJ, FishbeinMC, MacLellanWR, BurdickMD, BelperioJA, StrieterRM. 2003. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation, 107(15):1958–1961.
46.
KobayashiM, SaitohS, TanimuraN, TakahashiK, KawasakiK, NishijimaM, FujimotoY, FukaseK, kashi-TakamuraS, MiyakeK. 2006. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol, 176(10):6211–6218.
47.
KumarH, KawaiT, AkiraS. 2011. Pathogen recognition by the innate immune system. Int Rev Immunol, 30(1):16–34.
48.
LiuJ, DuanY, ChengX, ChenX, XieW, LongH, LinZ, ZhuB. 2011. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun, 407(2):348–354.
49.
LuoMY, YangBL, YeF, WuX, PengS, YiB, WangW, ZhuW, LuoH, WenJG, CaiWJ, SchaperJ, SchaperW. 2011. Collateral vessel growth induced by femoral artery ligature is impaired by denervation. Mol Cell Biochem, 354(1–2):219–229.
50.
MaZ, QinH, BenvenisteEN. 2001. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha 1. J Immunol, 167(9):5150–5159.
51.
McCartyMF, BielenbergD, DonawhoC, BucanaCD, FidlerIJ. 2002. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis, 19(7):609–615.
52.
MedinaRJ, O'NeillCL, O'dohertyTM, KnottH, Guduric-FuchsJ, GardinerTA, StittAW. 2011. Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. Mol Med, 17(9–10):1045–1055.
53.
MeierP, GloeklerS, ZbindenR, BeckhS, de MarchiSF, ZbindenS, WustmannK, BillingerM, VogelR, CookS, WenaweserP, TogniM, WindeckerS, MeierB, SeilerC. 2007. Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation, 116(9):975–983.
54.
NelissenI, RonsseI, Van DammeJ, OpdenakkerG. 2002. Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta. J Leukoc Biol, 71(1):89–98.
55.
OhSS, MoonC, KimDH, SongH, ParkS, FuY, KimKD. 2012. Adenovirally delivered IFN-beta exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation. Int J Mol Med, 29(6):1153–1157.
56.
OhtoU, TanjiH, ShimizuT. 2014. Structure and function of toll-like receptor 8. Microbes Infect, 16(4):273–282.
57.
OkabeY, KawaneK, AkiraS, TaniguchiT, NagataS. 2005. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med, 202(10):1333–1339.
58.
PaludanSR, BowieAG. 2013. Immune sensing of DNA. Immunity, 38(5):870–880.
59.
ParkJA, JoeYA, KimTG, HongYK. 2006. Potentiation of antiglioma effect with combined temozolomide and interferon-beta. Oncol Rep, 16(6):1253–1260.
60.
PiccardH, MuschelRJ, OpdenakkerG. 2012. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol, 82(3):296–309.
61.
PlataniasLC. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol, 5(5):375–386.
62.
RayChaudhuryA, FrischerH, MalikAB. 1996. Inhibition of endothelial cell proliferation and bFGF-induced phenotypic modulation by nitric oxide. J Cell Biochem, 63(2):125–134.
RomagnaniP, LasagniL, AnnunziatoF, SerioM, RomagnaniS. 2004. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol, 25(4):201–209.
SchirmerSH, FledderusJO, BotPT, MoerlandPD, HoeferIE, BaanJJr., HenriquesJP, van der SchaafRJ, VisMM, HorrevoetsAJ, PiekJJ, van RoyenN. 2008. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res, 102(10):1286–1294.
69.
SchirmerSH, van NooijenFC, PiekJJ, van RoyenN. 2009. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart, 95(3):191–197.
70.
SchroderK, HertzogPJ, RavasiT, HumeDA. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol, 75(2):163–189.
ShiremanPK. 2007. The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg, 45Suppl A:A48–A56.
73.
SimonsM. 2005. Angiogenesis: where do we stand now?. Circulation, 111(12):1556–1566.
74.
SomersEC, ZhaoW, LewisEE, WangL, WingJJ, SundaramB, KazerooniEA, McCuneWJ, KaplanMJ. 2012. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One, 7(5):e37000.
75.
StabileE, BurnettMS, WatkinsC, KinnairdT, BachisA, la SalaA, MillerJM, ShouM, EpsteinSE, FuchsS. 2003. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation, 108(2):205–210.
76.
StabileE, KinnairdT, la SalaA, HansonSK, WatkinsC, CampiaU, ShouM, ZbindenS, FuchsS, KornfeldH, EpsteinSE, BurnettMS. 2006. CD8+ T lymphocytes regulate the arteriogenic response to ischemia by infiltrating the site of collateral vessel development and recruiting CD4+ mononuclear cells through the expression of interleukin-16. Circulation, 113(1):118–124.
77.
StephanD, SanH, YangZY, GordonD, GoelzS, NabelGJ, NabelEG. 1997. Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta-interferon. Mol Med, 3(9):593–599.
78.
StetsonDB, MedzhitovR. 2006. Type I interferons in host defense. Immunity, 25(3):373–381.
79.
StoeltzingO, AhmadSA, LiuW, McCartyMF, WeyJS, ParikhAA, FanF, ReinmuthN, KawaguchiM, BucanaCD, EllisLM. 2003. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res, 63(12):3370–3377.
80.
SweeneyCM, LonerganR, BasdeoSA, KinsellaK, DunganLS, HigginsSC, KellyPJ, CostelloeL, TubridyN, MillsKH, FletcherJM. 2011. IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun, 25(6):1170–1181.
81.
SzekaneczZ, KochAE. 2009. Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol, 51(1):1–7.
82.
TakanoS, IshikawaE, MatsudaM, YamamotoT, MatsumuraA. 2014. Interferon-beta inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. Int J Oncol, 45(5):1837–1846.
83.
TaylorKL, LeamanDW, GraneR, MechtiN, BordenEC, LindnerDJ. 2008. Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. J Interferon Cytokine Res, 28(12):733–740.
TzimaE, Irani-TehraniM, KiossesWB, DejanaE, SchultzDA, EngelhardtB, CaoG, DeLisserH, SchwartzMA. 2005. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature, 437(7057):426–431.
86.
UrbichC, De SouzaAI, RossigL, YinX, XingQ, ProkopiM, DrozdovI, SteinerM, BreussJ, XuQ, DimmelerS, MayrM. 2011. Proteomic characterization of human early pro-angiogenic cells. J Mol Cell Cardiol, 50(2):333–336.
87.
UrbichC, HeeschenC, AicherA, DernbachE, ZeiherAM, DimmelerS. 2003. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation, 108(20):2511–2516.
88.
van BaarsenLG, van der Pouw KraanTC, KragtJJ, BaggenJM, RustenburgF, HooperT, MeilofJF, FeroMJ, DijkstraCD, PolmanCH, VerweijCL. 2006. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun, 7(6):522–531.
89.
van den BorneP, HaverslagRT, BrandtMM, ChengC, DuckersHJ, QuaxPH, HoeferIE, PasterkampG, de KleijnDP. 2014a. Absence of chemokine (C-x-C motif) ligand 10 diminishes perfusion recovery after local arterial occlusion in mice. Arterioscler Thromb Vasc Biol, 34(3):594–602.
90.
van den BorneP, QuaxPH, HoeferIE, PasterkampG. 2014b. The multifaceted functions of CXCL10 in cardiovascular disease. Biomed Res Int, 2014:1–11.
91.
van der LaanAM, PiekJJ, van RoyenN. 2009. Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol, 6(8):515–523.
92.
van der LaanAM, SchirmerSH, de VriesMR, KoningJJ, VolgerOL, FledderusJO, BastiaansenAJ, HollanderMR, BaggenJM, KochKT, BaanJJr., HenriquesJP, van der SchaafRJ, VisMM, MebiusRE, van der Pouw KraanTC, QuaxPH, PiekJJ, HorrevoetsAJ, van RoyenN. 2012. Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. Eur Heart J, 33:1076–1084.
93.
van der Pouw KraanTC, van der LaanAM, PiekJJ, HorrevoetsAJ. 2012. Surfing the data tsunami, a bioinformatic dissection of the proangiogenic monocyte. Vasc Pharmacol, 56(5–6):297–305.
94.
van der Pouw KraanTC, WijbrandtsCA, van BaarsenLG, VoskuylAE, RustenburgF, BaggenJM, IbrahimSM, FeroM, DijkmansBA, TakPP, VerweijCL. 2007. Rheumatoid Arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheumat Dis, 66(8):1008–1014.
95.
van RoyenN, HoeferI, BuschmannI, HeilM, KostinS, DeindlE, VogelS, KorffT, AugustinH, BodeC, PiekJJ, SchaperW. 2002. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J, 16(3):432–434.
96.
van RoyenN, PiekJJ, BuschmannI, HoeferI, VoskuilM, SchaperW. 2001. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res, 49(3):543–553.
97.
van RoyenN, PiekJJ, SchaperW, FultonWF. 2009. A critical review of clinical arteriogenesis research. J Am Coll Cardiol, 55(1):17–25.
98.
van WeelV, ToesRE, SeghersL, DeckersMM, de VriesMR, EilersPH, SipkensJ, SchepersA, EeftingD, van HinsberghV, van BockelJH, QuaxPH. 2007. Natural killer cells and CD4+ T-cells modulate collateral artery development. Arterioscler Thromb Vasc Biol, 27(11):2310–2318.
99.
VilcekJ. 2006. Fifty years of interferon research: aiming at a moving target. Immunity, 25(3):343–348.
100.
WuS, WuX, ZhuW, CaiWJ, SchaperJ, SchaperW. 2010. Immunohistochemical study of the growth factors, aFGF, bFGF, PDGF-AB, VEGF-A and its receptor (Flk-1) during arteriogenesis. Mol Cell Biochem, 343(1–2):223–229.
YanaiH, SavitskyD, TamuraT, TaniguchiT. 2009. Regulation of the cytosolic DNA-sensing system in innate immunity: a current view. Curr Opin Immunol, 21(1):17–22.
103.
YoshidaA, Anand-ApteB, ZetterBR. 1996. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors, 13(1–2):57–64.
104.
ZeiherAM, FisslthalerB, Schray-UtzB, BusseR. 1995. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res, 76(6):980–986.
105.
ZhangLN, VelichkoS, VinceletteJ, FitchRM, VergonaR, SullivanME, CrozeE, WangYX. 2008a. Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice. Atherosclerosis, 197(1):204–211.
106.
ZhangSY, Boisson-DupuisS, ChapgierA, YangK, BustamanteJ, PuelA, PicardC, AbelL, JouanguyE, CasanovaJL. 2008b. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev, 226:29–40.
107.
ZhengH, QianJ, CarboneCJ, LeuNA, BakerDP, FuchsSY. 2011. Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood, 118(14):4003–4006.
